A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma. Leuk Lymphoma 2017 Sep;58(9):1-2
Date
03/11/2017Pubmed ID
28278718Pubmed Central ID
PMC5497734DOI
10.1080/10428194.2017.1289527Scopus ID
2-s2.0-85013152251 (requires institutional sign-in at Scopus site) 3 CitationsAuthor List
Cohen JB, Maddocks KJ, Huang Y, Christian BA, Jaglowski SM, Flowers CR, Blum KAAuthor
Samantha M. Jaglowski MD, MPH Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdultAged
Antineoplastic Agents
Azepines
Drug Resistance, Neoplasm
Female
Humans
Lymphoma, B-Cell
Lymphoma, Non-Hodgkin
Male
Middle Aged
Protein Kinase Inhibitors
Pyrimidines
Recurrence
Retreatment
Treatment Outcome
